370 results
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
shareholders on a virtual data room provided by ImmunoGen. Access to and use of this virtual data room will be subject to satisfactory verification … of shareholder status and compliance with applicable Massachusetts law. To obtain access to the virtual data room, please contact ImmunoGen by email
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
data room provided by ImmunoGen. Access to and use of this virtual data room will be subject to satisfactory verification of shareholder status … and compliance with applicable Massachusetts law. To obtain access to the virtual data room, please contact ImmunoGen by email at IMGNShareholder
DEFA14A
EX-99.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit
DEFA14A
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
and Warranties
Article V COVENANTS
Section 5.1.
Covenants of the Company
Section 5.2.
Access to Information; Confidentiality
Section 5.3.
Acquisition Proposals … access to any material Trade Secrets of or held by any of the Company or any of its Subsidiaries, is subject to a written, valid agreement assigning
8-K
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
and Warranties
Article V COVENANTS
Section 5.1.
Covenants of the Company
Section 5.2.
Access to Information; Confidentiality
Section 5.3.
Acquisition Proposals … access to any material Trade Secrets of or held by any of the Company or any of its Subsidiaries, is subject to a written, valid agreement assigning
8-K
EX-99.1
jrucrxrax
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
ddmu8mal1w 2l7
2 Nov 23
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
6:35am
8-K
EX-99.1
ky8et3j1zawxkxf6whbg
31 Jul 23
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
6:40am
8-K
EX-1.1
clg qqe4fooyobibit
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
ahj3 e89u
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
82m71d
3 May 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
d3fli4px 0ub6ad
3 May 23
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
6:35am
8-K
EX-99.1
2xt3wk fjhrj
28 Apr 23
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
6:36am